Mirum Pharmaceuticals, Inc. (MIRM) Financial Statements (2026 and earlier)

Company Profile

Business Address 989 EAST HILLSDALE BOULEVARD, SUITE 300
FOSTER CITY, CA 94404
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments280,315286,326151,719156,541231,820116,660
Cash and cash equivalent222,503286,32628,00331,340142,08611,970
Short-term investments57,812 123,716125,20189,734104,690
Receivables78,28667,96823,9943,267  
Inventory, net of allowances, customer advances and progress billings22,40322,3125,5651,513  
Inventory22,40322,3125,5651,513  
Other undisclosed current assets11,78410,9358,9475,2714,5302,703
Total current assets:392,788387,541190,225166,592236,350119,363
Noncurrent Assets
Operating lease, right-of-use asset8,6751,2841,4311,5691,9492,361
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization1,1397069149811,2931,372
Long-term investments and receivables12,526  4,983 23,292
Long-term investments12,526  4,983 23,292
Intangible asset, including goodwill, after accumulated amortization249,819252,92558,95418,740  
Intangible asset, excluding goodwill, after accumulated amortization249,819252,92558,95418,740  
Other noncurrent assets5,3824,1651,3821,7861,272324
Other undisclosed noncurrent assets425 100,000100,000  
Total noncurrent assets:277,966259,080162,681128,0594,51427,349
TOTAL ASSETS:670,754646,621352,906294,651240,864146,712
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities124,84285,96062,70839,88916,56212,679
Accounts payable14,6187,4168,6909,1663,1513,351
Accrued liabilities110,22478,54454,01830,72313,4119,328
Debt      397
Derivative instruments and hedges, liabilities   1,0901,9961,264 
Other undisclosed current liabilities 1,7091,104931711636 
Total current liabilities:126,55187,06464,72942,59618,46213,076
Noncurrent Liabilities
Long-term debt and lease obligation308,082306,421 1,9032,6273,251
Long-term debt, excluding current maturities308,082306,421    
Liabilities, other than long-term debt10,4814,4665,789172936
Other liabilities2,5093,8494,532172936
Operating lease, liability7,9726171,2571,9032,6273,251
Other undisclosed noncurrent liabilities   140,351129,92347,651 
Total noncurrent liabilities:318,563310,887146,140131,84350,3073,287
Total liabilities:445,114397,951210,869174,43968,76916,363
Equity
Equity, attributable to parent225,640248,670142,037120,212172,095130,349
Common stock554332
Additional paid in capital870,189803,260535,074377,403345,180200,119
Accumulated other comprehensive income (loss)(373)1,644(217)(35)83129
Accumulated deficit(644,181)(556,239)(392,824)(257,159)(173,171)(69,901)
Total equity:225,640248,670142,037120,212172,095130,349
TOTAL LIABILITIES AND EQUITY:670,754646,621352,906294,651240,864146,712

Income Statement (P&L) ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues336,888186,37477,06219,138  
Gross profit:336,888186,37477,06219,138  
Operating expenses(424,494)(295,528)(208,282)(192,551)(104,296)(54,743)
Operating loss:(87,606)(109,154)(131,220)(173,413)(104,296)(54,743)
Nonoperating income (expense)15,00510,9114,222(216)1,3672,211
Investment income, nonoperating13,79213,7353,8573661,5592,232
Other nonoperating income (expense)1,213(2,824)365(582)(192)(21)
Interest and debt expense(14,311)(49,076)    
Loss from continuing operations before equity method investments, income taxes:(86,912)(147,319)(126,998)(173,629)(102,929)(52,532)
Other undisclosed income (loss) from continuing operations before income taxes  (15,105)(15,073)89,678(335) 
Loss from continuing operations before income taxes:(86,912)(162,424)(142,071)(83,951)(103,264)(52,532)
Income tax expense (benefit)(1,030)(991)6,406(37)(6)(21)
Loss from continuing operations:(87,942)(163,415)(135,665)(83,988)(103,270)(52,553)
Loss before gain (loss) on sale of properties:(83,988)(103,270)(52,553)
Net loss available to common stockholders, basic:(87,942)(163,415)(135,665)(83,988)(103,270)(52,553)
Other undisclosed net loss available to common stockholders, diluted   (914)   
Net loss available to common stockholders, diluted:(87,942)(163,415)(136,579)(83,988)(103,270)(52,553)

Comprehensive Income ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(87,942)(163,415)(135,665)(83,988)(103,270)(52,553)
Comprehensive loss:(87,942)(163,415)(135,665)(83,988)(103,270)(52,553)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(2,017)1,861(182)(118)(46)129
Comprehensive loss, net of tax, attributable to parent:(89,959)(161,554)(135,847)(84,106)(103,316)(52,424)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: